狄诺塞麦治疗骨转移效果怎么样呢?
On June 13, 2013, it was approved to treat adults and adolescents with giant cell tumor of bone (GCTB), a rare and usually noncancerous tumor. On May 27, 2019, Amgen China announced that denosumab injection has been approved by the National Medical Products Administration for the treatment of giant cell tumors of bone that are unresectable or that may result in severe functional impairment after surgical resection, including adults and adolescent patients with skeletal maturity (defined as at least 1 mature long bone and body weight >45 kg). The launch of denosumab in my country will bring new hope to domestic patients with bone metastasis. How effective is denosumab in treating bone metastases?
Three clinical randomized, double-blind trials included a total of 5723 tumor patients: Trial 1 was breast cancer patients with bone metastasis; Trial 2 was prostate cancer patients with bone metastasis; Trial 3 was solid tumors other than breast cancer and prostate cancer with bone metastasis and multiple myeloma. The efficacy of denosumab was compared with that of zoledronic acid (a bisphosphonate) in breast cancer, prostate cancer and other solid tumors with bone metastases, as well as in multiple myeloma.
Comprehensive analysis of these three studies showed that compared with zoledronic acid: denosumab prolonged the time to the patient's first adverse bone event (ARE) by 17%, or significantly delayed the median time to the first SRE by 8.2 months (27.6 months vs. 19.4 months for zoledronic acid); denosumab prolonged the time from the first to the recurrence of SRE in the study by 18%. Denosumab also significantly prolonged the time to worsening pain compared with zoledronic acid in patients with mild or no pain at study entry. Based on this, the NCCN guidelines also recommend the use of denosumab for patients with bone metastases from solid tumors.
Medical Travel is an overseas medical service company. Medical Travel cooperates with foreign pharmacies and pharmaceutical companies and can directly help patients purchase genuine products.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)